TrialAn Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Trial details
- Registry ID
- NCT07365332
- Phase
- Phase 3
IKT
Inhibikase Therapeutics
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
2Trials in this database
2Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)NCT07365332 | Inhibikase Therapeutics | Phase 3 | Recruiting | 2029-06Estimated |
| Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)NCT07632898 | Inhibikase Therapeutics | Phase 3 | Not yet recruiting | 2030-06-30Estimated |
Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Trial details
- Registry ID
- NCT07632898
- Phase
- Phase 3
Latest recorded trial changes
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
NCT07365332 · Inhibikase Therapeutics
Recruitment status changed
− Before
Not yet recruiting
+ After
Recruiting
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
NCT07365332 · Inhibikase Therapeutics
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: [Part A] To evaluate the effect on PVR in participants with WHO Group 1 PAH treated with IKT-001 compared to placebo Measure: [Part B] To characterize the effects of IKT-001 on symptoms and characteristics of Pulmonary Arterial Hypertension compared to placebo
+ After
Measure: [Part A] To evaluate the effect on Pulmonary Vascular Resistance (PVR) in participants with WHO Group 1 PAH treated with IKT-001 compared to placebo Measure: [Part B] To characterize the effects of IKT-001 on symptoms and characteristics of Pulmonary Arterial Hypertension compared to placebo